Mitral Valve Prolapse Management

Diagnosis and Evaluation

The American College of Cardiology recommends confirming the diagnosis of MVP with physical examination focusing on the characteristic midsystolic click, often followed by a late systolic murmur, and two-dimensional and Doppler echocardiography showing valve prolapse ≥2 mm above mitral annulus in long-axis parasternal view, leaflet thickness ≥5 mm, and mitral regurgitation typically presenting as high-velocity eccentric jet in late systole 1
Two-dimensional and Doppler echocardiography is the most useful diagnostic test for MVP, as stated by the American Heart Association and the American College of Cardiology 2, 1
Diagnostic criteria for MVP include valve prolapse ≥2 mm above mitral annulus in long-axis parasternal view, leaflet thickness ≥5 mm, and mitral regurgitation typically presenting as high-velocity eccentric jet in late systole, as recommended by the American College of Cardiology 2, 1
Evaluate for rheumatic features by looking for echocardiographic evidence of rheumatic involvement, checking for history of rheumatic fever with Jones criteria, and assessing for mitral stenosis (uncommon in pure MVP) 3
Rheumatic heart disease has distinct echocardiographic features, including commissural fusion, leaflet thickening at the edges, restricted leaflet mobility, and often associated with mitral stenosis 4

The American College of Cardiology recommends that routine repetition of echocardiography is not indicated for asymptomatic patients who have MVP and no MR or MVP and mild MR with no changes in clinical signs or symptoms 1
Clinical follow-up every 3-5 years is suggested for asymptomatic patients with no/mild mitral regurgitation 1
The American College of Cardiology recommends clinical evaluation every 3-5 years for asymptomatic patients with no/mild mitral regurgitation, and annual follow-up with serial echocardiography for patients with high-risk features 1
Regular clinical follow-up and periodic echocardiographic assessment are recommended for all patients with MVP, as stated by the American College of Cardiology 2, 5
Risk assessment in MVP focuses on cardiac parameters rather than hematological findings, including leaflet thickness ≥5 mm, moderate to severe mitral regurgitation, left ventricular dysfunction (EF ≤60%), left atrial enlargement, and flail leaflet, as reported by the European Society of Cardiology 1

The American Heart Association recommends warfarin therapy for patients with MVP and atrial fibrillation who are older than 65 years, have hypertension, have mitral regurgitation murmur, or have a history of heart failure 1
Aspirin therapy (75-325 mg per day) is recommended for symptomatic patients with MVP who experience cerebral transient ischemic attacks, according to the American College of Cardiology 1
Regular exercise and normal lifestyle should be encouraged in most patients with MVP, as stated by the American College of Cardiology 1
Reassurance is a major component of management for MVP patients with mild symptoms, as most have a benign prognosis, according to the American College of Cardiology 1
Beta blockers may be used to manage tachyarrhythmias and increased adrenergic symptoms in patients with MVP, as suggested by the American College of Cardiology 2
Volume expansion, support stockings, and mineralocorticoid therapy or clonidine may be used to manage orthostatic symptoms in patients with MVP, as recommended by the American College of Cardiology 2

MVP can lead to complications such as mitral regurgitation, atrial fibrillation, congestive heart failure, endocarditis, ventricular arrhythmias, and sudden cardiac death, as warned by the American College of Cardiology 2, 6
Cerebral ischemic episodes and stroke are also potential complications of MVP, as noted by the American Heart Association 2
Surgical intervention (repair preferred over replacement) may be indicated for symptomatic severe MR, asymptomatic severe MR with LV dysfunction (EF <60%), LV end-systolic dimension ≥40 mm, new onset atrial fibrillation, or pulmonary hypertension (pulmonary artery systolic pressure >50 mmHg), as recommended by the American College of Cardiology 5
Referral to centers experienced in mitral valve repair is strongly recommended when surgery is indicated, according to the American Heart Association 1
Implantable cardioverter-defibrillator (ICD) therapy should be considered for patients with high-risk features and documented sustained ventricular tachyarrhythmias, according to the European Society of Cardiology 7

Overdiagnosis of rheumatic heart disease based solely on elevated ASO titers without other supporting evidence 2
Unnecessary anticoagulation in MVP patients without appropriate indications, exposing them to bleeding risks 3
Missing true rheumatic involvement by assuming all valve abnormalities are due to MVP 4
The American College of Cardiology/American Heart Association guidelines do not recommend treating MVP patients for rheumatic heart disease based solely on elevated ASO titers 2